Skip to main content
NewslettersWatchlist

Novavax Inc(NVAX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low4.69
Day High4.94
Open:4.84
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole
Motley Fool
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street
Motley Fool
Better Buy: Bluebird Bio Vs. Novavax
Motley Fool
Down 60% From Its 52-Week High, Is Novavax Stock a Buy?
Motley Fool
1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague
Motley Fool
1 Beaten-Down Stock That's Still Not Worth Buying
Motley Fool
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street
Motley Fool
Is Novavax a Buy Now?
Motley Fool
1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?
Motley Fool
Has Novavax Just Solved Its Biggest Problem?
Motley Fool
Better Bull Market Buy: Novavax vs. Pfizer
Motley Fool
Where Will Novavax Be in 10 Years?
Motley Fool
3 Beaten-Down Growth Stocks that Could Take off in the New Bull Market
Motley Fool
Better Recovery Story Buy: Novavax vs. Teladoc
Motley Fool
Could Novavax Stock Help You Become a Millionaire?
Motley Fool
3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts
Motley Fool
1 Reason to Buy Novavax Stock, and 3 (Better) Reasons to Sell
Motley Fool
1 Reason to Buy Novavax Stock Hand Over Fist and 1 Reason to Sell
Motley Fool
Is It Too Late to Buy Novavax Stock?
Motley Fool
Where Will Novavax Be in 5 Years?
Motley Fool
Novavax Stock May Soar 379%, According to Wall Street. Is the Stock a Buy Right Now?
Motley Fool
3 Turnaround Stocks With 151% to 600% Upside in 2024, According to Select Wall Street Analysts

Profile

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple studies.'Novavax developed its own coronavirus vaccine NVX-CoV2373. The company is currently marketing two versions of NVX-CoV2373, one marketed in partnership with the Serum Institute of India under the trade name Covovax and another version produced by Novavax and marketed under the trade name Nuvaxovid.'Novavax developed NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix M adjuvant for senior patients aged 65 years and above.'ResVax a respiratory syncytial virus vaccine is being developed to protect infants by immunizing mothers against the disease. Novavax is discussing the opportunity to bring ResVax to the market globally with the help of commercial partners.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.